Apricus Biosc Inc (APRI) 0.32 $APRI
Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
Globe Newswire - Mon Aug 01, 6:00AM CDT
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 4, 2016 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, August 4, 2016, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
APRI: 0.32 (+0.01)
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon
Globe Newswire - Wed Jul 27, 6:00AM CDT
SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Republic of Lebanon Ministry of Public Health has granted market approval to Vitaros(R), a topical cream indicated for the treatment of patients with erectile dysfunction. Apricus has an exclusive license agreement with Elis Pharmaceuticals ("Elis"
for the commercialization of Vitaros in the United Arab Emirates, Oman, Bahrain, Qatar, Saudi Arabia and Kuwait (the "Gulf States" and part of the Middle East.
APRI: 0.32 (+0.01)
Dr. Bassam Damaj Appointed to Hispanica International Delights of America, Inc. Board of Directors
Marketwired - Thu Jul 14, 5:00AM CDT
NEW YORK, NY--(Marketwired - Jul 14, 2016) - Hispanica International Delights of America, Inc. (OTC PINK: HISP), a diversified food and beverage company in the Hispanic and ethnic food industry, announced today the appointment of Bassam Damaj, PhD to its Board of Directors. Dr. Damaj brings with him the expertise of navigating the public markets. He currently serves as President & CEO of Innovus Pharma. Prior to joining Innovus, Dr. Damaj served as President & Chief Executive Officer of Apricus Biosciences, Inc., from December 2009 until November 2012. At Apricus, he was responsible for the approval of its lead drug, Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion-dollar partnerships between Apricus and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda.
APRI: 0.32 (+0.01), NVS: 83.07 (-0.19)
Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Wed Jul 06, 7:08AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) (the "Company" or "Apricus", a biopharmaceutical company focusing on the development and commercialization of novel therapeutics to treat areas of unmet medical need, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital".
APRI: 0.32 (+0.01)
Biocom Appoints New Directors to its Board
PR Newswire - Tue Jun 07, 11:01AM CDT
Biocom, the association representing the Southern California life science community, today announced the appointment of 13 new directors to its board, including the appointment of Charles Dadswell, senior vice president and general counsel for Illumina, and Rich Pascoe, chief executive officer of Apricus Biosciences, to the executive committee of Biocom's board. In addition, Biocom announced that Magda Marquet, Ph.D., co-founder of Ajinomoto Althea and AltheaDx, and Brent D. Jacobs, executive director in the global life sciences practice group at Cushman & Wakefield, were named as life directors, a prestigious and special class of director.
APRI: 0.32 (+0.01)
ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 4:05PM CDT
ARIAD (ARIA) announced the initiation of a phase I/IIstudy on AP32788 for the treatment of non-small cell lung cancer with specific mutations in EGFR or HER2.
APRI: 0.32 (+0.01), JNP: 7.50 (-0.04), ARIA: 9.71 (+0.20)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 40.32 (-0.18), ARQL: 1.68 (+0.02), APRI: 0.32 (+0.01), RPRX: 2.06 (-0.06)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 40.32 (-0.18), JAZZ: 150.53 (-0.44), ARQL: 1.68 (+0.02), APRI: 0.32 (+0.01)
Apricus reports 1Q loss
Automated Insights - Mon May 09, 6:49AM CDT
SAN DIEGO (AP) _ Apricus Biosciences Inc. (APRI) on Monday reported a loss of $2.5 million in its first quarter.
APRI: 0.32 (+0.01)
Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
Globe Newswire - Mon May 09, 6:00AM CDT
Vitaros(R) U.S. NDA Re-Submission on Schedule for 3Q 2016
APRI: 0.32 (+0.01)
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 1:44PM CDT
In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, "2H 2016" should instead be "Q3 2016."
APRI: 0.32 (+0.01)
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 6:01AM CDT
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine
APRI: 0.32 (+0.01)
Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2016 financial results will be released on Monday, May 9, 2016 at 7:00 a.m. Eastern Time.
APRI: 0.32 (+0.01)
Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
Globe Newswire - Mon Aug 01, 6:00AM CDT
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 4, 2016 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, August 4, 2016, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
APRI: 0.32 (+0.01)
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon
Globe Newswire - Wed Jul 27, 6:00AM CDT
SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Republic of Lebanon Ministry of Public Health has granted market approval to Vitaros(R), a topical cream indicated for the treatment of patients with erectile dysfunction. Apricus has an exclusive license agreement with Elis Pharmaceuticals ("Elis"
for the commercialization of Vitaros in the United Arab Emirates, Oman, Bahrain, Qatar, Saudi Arabia and Kuwait (the "Gulf States" and part of the Middle East. APRI: 0.32 (+0.01)
Dr. Bassam Damaj Appointed to Hispanica International Delights of America, Inc. Board of Directors
Marketwired - Thu Jul 14, 5:00AM CDT
NEW YORK, NY--(Marketwired - Jul 14, 2016) - Hispanica International Delights of America, Inc. (OTC PINK: HISP), a diversified food and beverage company in the Hispanic and ethnic food industry, announced today the appointment of Bassam Damaj, PhD to its Board of Directors. Dr. Damaj brings with him the expertise of navigating the public markets. He currently serves as President & CEO of Innovus Pharma. Prior to joining Innovus, Dr. Damaj served as President & Chief Executive Officer of Apricus Biosciences, Inc., from December 2009 until November 2012. At Apricus, he was responsible for the approval of its lead drug, Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion-dollar partnerships between Apricus and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda.
APRI: 0.32 (+0.01), NVS: 83.07 (-0.19)
Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Wed Jul 06, 7:08AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) (the "Company" or "Apricus"
, a biopharmaceutical company focusing on the development and commercialization of novel therapeutics to treat areas of unmet medical need, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital". APRI: 0.32 (+0.01)
Biocom Appoints New Directors to its Board
PR Newswire - Tue Jun 07, 11:01AM CDT
Biocom, the association representing the Southern California life science community, today announced the appointment of 13 new directors to its board, including the appointment of Charles Dadswell, senior vice president and general counsel for Illumina, and Rich Pascoe, chief executive officer of Apricus Biosciences, to the executive committee of Biocom's board. In addition, Biocom announced that Magda Marquet, Ph.D., co-founder of Ajinomoto Althea and AltheaDx, and Brent D. Jacobs, executive director in the global life sciences practice group at Cushman & Wakefield, were named as life directors, a prestigious and special class of director.
APRI: 0.32 (+0.01)
ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 4:05PM CDT
ARIAD (ARIA) announced the initiation of a phase I/IIstudy on AP32788 for the treatment of non-small cell lung cancer with specific mutations in EGFR or HER2.
APRI: 0.32 (+0.01), JNP: 7.50 (-0.04), ARIA: 9.71 (+0.20)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 40.32 (-0.18), ARQL: 1.68 (+0.02), APRI: 0.32 (+0.01), RPRX: 2.06 (-0.06)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 40.32 (-0.18), JAZZ: 150.53 (-0.44), ARQL: 1.68 (+0.02), APRI: 0.32 (+0.01)
Apricus reports 1Q loss
Automated Insights - Mon May 09, 6:49AM CDT
SAN DIEGO (AP) _ Apricus Biosciences Inc. (APRI) on Monday reported a loss of $2.5 million in its first quarter.
APRI: 0.32 (+0.01)
Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
Globe Newswire - Mon May 09, 6:00AM CDT
Vitaros(R) U.S. NDA Re-Submission on Schedule for 3Q 2016
APRI: 0.32 (+0.01)
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 1:44PM CDT
In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, "2H 2016" should instead be "Q3 2016."
APRI: 0.32 (+0.01)
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 6:01AM CDT
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine
APRI: 0.32 (+0.01)
Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2016 financial results will be released on Monday, May 9, 2016 at 7:00 a.m. Eastern Time.
APRI: 0.32 (+0.01)
